The overall findings of the Bicalutamide Early Prostate Cancer Program demonstrate that in addition to standard care, bicalutamide resulted in a significant reduction in the risk of objective progression. PSA, prostate-specific antigen; HR, hazard ratio; E, events; CI, confidence interval. Reproduced with permission from See.32